v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current Assets    
Cash $ 14,774 $ 6,060
Total Current Assets 14,774 6,060
Equipment, net of accumulated depreciation of $307 and $251 at December 31, 2025 and 2024, respectively 56
Operating lease right-of-use asset 4,272 6,835
Security deposit 1,995 1,995
TOTAL ASSETS 21,041 14,946
Current Liabilities    
Accounts payable and accrued liabilities 1,084,763 922,083
Shareholders’ notes payable 49,000 49,000
Lease liability – short term portion 2,860 988
Accrued interest payable 19,279 15,439
Total Current Liabilities 2,319,968 1,471,012
Lease liability – long term portion 3,684 6,544
Total liabilities 2,323,652 1,477,556
Commitments and contingencies  
Stockholders’ Deficit:    
Preferred stock, $0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at December 31, 2025 and December 31, 2024
Common stock, $0.0001 par value; 80,000,000 shares authorized; 18,754,739 and 18,522,295 shares issued and outstanding at December 31, 2025 and 2024, respectively 1,875 1,852
Additional paid in capital 15,679,131 14,115,560
Stock subscription receivable (125,000) (150,000)
Accumulated deficit (17,858,617) (15,430,022)
Total Stockholders’ Deficit (2,302,611) (1,462,610)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 21,041 14,946
Sanovas Ophthalmology LLC [Member]    
Current Liabilities    
Due to related parties 674,842 15,709
Related Party [Member]    
Current Liabilities    
Due to related parties $ 489,224 $ 467,793